PD-1/PD-L1在炎性肠病中的研究进展  

Research Progress of PD-1/PD-L1 in Inflammatory Bowel Disease

作　　者：张宇[1] 师伟[1] 侯亚彬 郝崇华[1] ZHANG Yu;SHI Wei;HOU Yabin;HAO Chonghua(The Fifth Clinical Medical College of Shanxi Medical University,Taiyuan 030000,China)

机构地区：[1]山西医科大学第五临床医学院,太原030000

出　　处：《医学综述》2023年第4期640-644,共5页Medical Recapitulate

基　　金：山西省卫生健康委科研项目(2020032)。

摘　　要：炎性肠病(IBD)是一种病因和发病机制尚未明确的慢性非特异性肠道炎症性疾病,固有免疫应答、适应性免疫应答、肠道微生物菌群失调是IBD发病的关键因素。近年来,程序性细胞死亡受体1(PD-1)/程序性细胞死亡配体1(PD-L1)除了作为肿瘤免疫治疗的靶点外,在自身免疫性疾病方面的研究也成为焦点。PD-1/PD-L1信号分子作为维持机体对自身抗原耐受性的负性共刺激分子,通过调节肠道免疫与微生物菌群的平衡在维持肠道稳态中发挥重要作用。因此,深入研究PD-1/PD-L1在IBD中的作用机制,可以为IBD的治疗提供新思路。Inflammatory bowel disease(IBD)is a chronic non-specific inflammatory bowel disease with unknown etiology and pathogenesis,and innate immune responses,adaptive immune responses and gut microbiome disorders are key factors in the pathogenesis of IBD.Recently,programmed cell death receptor 1(PD-1)/programmed cell death-ligand 1(PD-L1)not only has been used as a target of tumor immunotherapy,but also is a focus of autoimmune diseases.The PD-1/PD-L1 is a group of negative co-stimulators and could maintain the body′s tolerance to its own antigens,playing an important role in maintaining intestinal homeostasis by regulating the balance of intestinal immunity and microbial flora.Therefore,an in-depth study of the mechanism of PD-1/PD-L1 in IBD can provide new ideas for the treatment of IBD.

关 键 词：炎性肠病 程序性细胞死亡受体1 程序性细胞死亡配体1 肠道免疫 微生物菌群 

分 类 号：R392[医药卫生—免疫学]